Written by the Core Power Peptides Research Team — biochemists and laboratory specialists compiling and verifying peptide research data. Learn about our quality standards →
Every treatment for sexual dysfunction before 2019 worked peripherally — PDE5 inhibitors like sildenafil act through vascular mechanisms. PT-141 broke that pattern by working centrally, activating melanocortin receptors in the hypothalamic regions governing sexual motivation itself. Its FDA approval that year made it the first non-hormonal, centrally acting treatment for female sexual dysfunction to clear the agency.
PT-141: Central Mechanism, Melanocortin Origins
PT-141 (bremelanotide) is a synthetic melanocortin agonist developed from melanotan II with structural modifications designed to target sexual function pathways while reducing cardiovascular side effects associated with its parent compound. In 2019, PT-141 received FDA approval under the brand name Vyleesi® for hypoactive sexual desire disorder (HSDD) in premenopausal women — making it the first non-hormonal, centrally acting treatment for female sexual dysfunction to receive FDA approval.
PT-141 is notable for its central rather than peripheral mechanism of action. Unlike PDE5 inhibitors (sildenafil, tadalafil) which work through peripheral vascular mechanisms, PT-141 activates melanocortin receptors in the CNS — specifically in hypothalamic regions involved in sexual motivation and arousal — producing a fundamentally different pharmacological profile that has attracted significant research interest.
Mechanism of Action
- MC4R Agonism (primary): Activates melanocortin-4 receptors in the hypothalamus, particularly the paraventricular nucleus (PVN), the brain region most directly linked to sexual motivation
- MC3R Agonism: Contributes to appetite modulation and neuroendocrine signaling
- Central Arousal Pathways: Increases dopaminergic tone in limbic reward circuits, enhancing motivational components of sexual behavior in research models
- Nitric Oxide: Downstream MC4R activation increases hypothalamic NO production, which contributes to genital engorgement responses in both sexes
- MC1R (minimal): Some melanin-stimulating effects, lower than melanotan II due to structural differences
Research and Clinical Data
Phase 3 RECONNECT Trials (leading to FDA approval)
- Two Phase 3 trials enrolled over 1,200 premenopausal women with HSDD
- Significant improvement in satisfying sexual events (SSEs) vs. placebo across both trials
- Female Sexual Function Index (FSFI) desire domain scores improved significantly
- Effect observed within 45 minutes of administration, peak at 1–2 hours
Male Sexual Function Research
- Phase 2 trials demonstrated dose-dependent erection facilitation in men with erectile dysfunction, including non-responders to PDE5 inhibitors
- Psychogenic ED research shows particularly strong response, as the central mechanism targets motivation rather than purely vascular function
Melanocortin System Research (Broader)
- PT-141 used as a research tool to investigate MC4R function in feeding, metabolic, and pain research
- Documented analgesic effects in rodent pain models (MC4R expressed in pain-modulating regions)
Dosage Reference for Research
| Context |
Dose |
Route |
Notes |
| FDA-approved (HSDD) |
1.75 mg |
SC auto-injector |
As needed, ≤1× per 24h |
| Phase 2 (male ED) |
4–20 mg |
SC |
Dose-finding studies |
| Rodent models |
0.1–1 mg/kg |
SC or IP |
Behavioral and metabolic studies |
HPLC Verified
PT-141 (Bremelanotide) 10mg
Purity: 99%+ HPLC
Format: Lyophilized Powder
Testing: Third-Party COA
$125
Buy Now
Frequently Asked Questions
How does PT-141 differ mechanistically from PDE5 inhibitors?
Entirely different site of action. PDE5 inhibitors such as sildenafil and tadalafil work through peripheral vascular mechanisms. PT-141 activates MC4R in the hypothalamic paraventricular nucleus — the region most directly linked to sexual motivation — producing effects on desire rather than vascular response alone. This is why Phase 2 research documented responses in men who had not responded to PDE5 inhibitors.
What is PT-141’s relationship to Melanotan 2?
PT-141 was developed from melanotan II with structural modifications intended to target sexual function pathways while reducing the cardiovascular effects associated with the parent compound.
Is PT-141 studied outside sexual function research?
Yes. Because MC4R is expressed in feeding, metabolic, and pain-modulating regions, PT-141 serves as a pharmacological probe for melanocortin system research generally — including documented analgesic effects in rodent pain models.
Compiled for research reference. PT-141 supplied by Core Power Peptides is intended for in vitro and laboratory use only — not for human consumption, and not medical advice.
